BR112013029761A2 - pró-drogas de monofosfato de purina para tratamento de infecções virais - Google Patents
pró-drogas de monofosfato de purina para tratamento de infecções viraisInfo
- Publication number
- BR112013029761A2 BR112013029761A2 BR112013029761A BR112013029761A BR112013029761A2 BR 112013029761 A2 BR112013029761 A2 BR 112013029761A2 BR 112013029761 A BR112013029761 A BR 112013029761A BR 112013029761 A BR112013029761 A BR 112013029761A BR 112013029761 A2 BR112013029761 A2 BR 112013029761A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- viral infections
- monophosphate prodrugs
- purine
- purine monophosphate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161488140P | 2011-05-19 | 2011-05-19 | |
| PCT/US2012/038165 WO2012158811A2 (en) | 2011-05-19 | 2012-05-16 | Purine monophosphate prodrugs for treatment of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013029761A2 true BR112013029761A2 (pt) | 2017-03-21 |
Family
ID=47177610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013029761A BR112013029761A2 (pt) | 2011-05-19 | 2012-05-16 | pró-drogas de monofosfato de purina para tratamento de infecções virais |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20140212382A1 (pt) |
| EP (1) | EP2710023A4 (pt) |
| KR (1) | KR20140033446A (pt) |
| CN (1) | CN103687866A (pt) |
| BR (1) | BR112013029761A2 (pt) |
| CA (1) | CA2836579A1 (pt) |
| MX (1) | MX2013013570A (pt) |
| RU (1) | RU2013125713A (pt) |
| WO (1) | WO2012158811A2 (pt) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8586781B2 (en) | 1998-04-02 | 2013-11-19 | Mbc Pharma, Inc. | Bone targeted therapeutics and methods of making and using the same |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| EP1294735A2 (en) | 2000-05-26 | 2003-03-26 | Novirio Pharmaceuticals Limited | Methods and compositions for treating flaviviruses and pestiviruses |
| CN1849142A (zh) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′－支链核苷和黄病毒突变 |
| RU2640582C2 (ru) | 2011-08-01 | 2018-01-10 | Мбс Фарма, Инк. | Производные витамина в6 нуклеотидов, ациклических нуклеотидов и ациклических нуклеозидных фосфонатов |
| TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
| EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| NZ702744A (en) | 2012-05-22 | 2016-12-23 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
| WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| UY34824A (es) | 2012-05-25 | 2013-11-29 | Janssen R & D Ireland | Nucleósidos de espirooxetano de uracilo |
| US9192621B2 (en) | 2012-09-27 | 2015-11-24 | Idenix Pharmaceuticals Llc | Esters and malonates of SATE prodrugs |
| EA030189B8 (ru) | 2012-10-08 | 2018-10-31 | Иденикс Фармасьютикалз Ллс | Аналоги 2'-хлоронуклеозидов для инфекции вгс |
| US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
| US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
| EP2970357A1 (en) | 2013-03-13 | 2016-01-20 | IDENIX Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
| US20140309164A1 (en) | 2013-04-12 | 2014-10-16 | Achillion Pharmaceuticals, Inc. | Deuterated nucleoside prodrugs useful for treating hcv |
| GB201306947D0 (en) * | 2013-04-17 | 2013-05-29 | Univ Leuven Kath | Novel antiviral compounds |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| US9815864B2 (en) | 2013-06-26 | 2017-11-14 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| US10449210B2 (en) * | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| CN105153257B (zh) * | 2014-06-12 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 索非布韦的制备方法 |
| EA201692535A1 (ru) | 2014-06-24 | 2017-05-31 | Элиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
| JP2017520545A (ja) | 2014-07-02 | 2017-07-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
| RU2764767C2 (ru) * | 2015-03-06 | 2022-01-21 | Атеа Фармасьютикалс, Инк. | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-С-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ |
| EP3128013A1 (en) * | 2015-08-07 | 2017-02-08 | Institut Univ. de Ciència i Tecnologia, S.A. | Deamination of organophosphorous-nucleosides |
| CA2979596A1 (en) | 2015-03-19 | 2016-09-22 | Institut Univ. De Ciencia I Tecnologia, S.A. | Deamination of organophosphorus-nucleosides |
| US10011629B2 (en) | 2015-05-01 | 2018-07-03 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
| MX2018006636A (es) * | 2015-12-08 | 2018-08-15 | Retrophin Inc | Fosfatos ciclicos y fosforoamidatos ciclicos para el tratamiento de trastornos neurologicos. |
| WO2017165489A1 (en) | 2016-03-23 | 2017-09-28 | Emory University | Antiviral agents for treating zika and dengue virus infections |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| US10711029B2 (en) | 2016-07-14 | 2020-07-14 | Atea Pharmaceuticals, Inc. | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| US20190169221A1 (en) * | 2016-08-12 | 2019-06-06 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| PL3512863T3 (pl) | 2016-09-07 | 2022-04-04 | Atea Pharmaceuticals, Inc. | 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA |
| SG10202012214WA (en) | 2017-02-01 | 2021-01-28 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
| WO2019140365A1 (en) * | 2018-01-12 | 2019-07-18 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
| CA3132832A1 (en) | 2018-04-09 | 2019-10-17 | Howard E. Gendelman | Antiviral prodrugs and formulations thereof |
| WO2019200005A1 (en) | 2018-04-10 | 2019-10-17 | Atea Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
| CN110950828B (zh) * | 2019-11-05 | 2021-08-17 | 中国人民解放军第二军医大学 | 一种黄芩素或其衍生物、制备方法与应用 |
| WO2021164848A1 (en) * | 2020-02-17 | 2021-08-26 | Katholieke Universiteit Leuven | Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| WO2022219173A1 (en) * | 2021-04-15 | 2022-10-20 | Dsm Ip Assets B.V. | Production of panthenol |
| EP4108654A1 (en) * | 2021-06-23 | 2022-12-28 | DSM IP Assets B.V. | Production of panthenol |
| WO2022265964A1 (en) * | 2021-06-14 | 2022-12-22 | VenatoRx Pharmaceuticals, Inc. | Orally-bioavailable nucleoside analogs |
| CN114249764A (zh) * | 2021-11-10 | 2022-03-29 | 宁波大学 | 一种磷酰胺酯类前药的中间体及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| WO2006121820A1 (en) * | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) * | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| WO2007017248A2 (en) * | 2005-08-08 | 2007-02-15 | Abbott Gmbh & Co. Kg | Itraconazole compositions with improved bioavailability |
| US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| KR101774429B1 (ko) * | 2009-02-06 | 2017-09-04 | 코크리스탈 파마, 아이엔씨. | 암 및 바이러스 감염 치료용 퓨린 뉴클레오시드 모노포스페이트 프로드럭 |
| NZ607996A (en) * | 2010-09-22 | 2014-07-25 | Alios Biopharma Inc | Substituted nucleotide analogs |
| EP2655392B1 (en) * | 2010-12-22 | 2018-04-18 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
-
2012
- 2012-05-16 RU RU2013125713/04A patent/RU2013125713A/ru not_active Application Discontinuation
- 2012-05-16 US US14/117,815 patent/US20140212382A1/en not_active Abandoned
- 2012-05-16 BR BR112013029761A patent/BR112013029761A2/pt not_active IP Right Cessation
- 2012-05-16 KR KR1020137033848A patent/KR20140033446A/ko not_active Application Discontinuation
- 2012-05-16 WO PCT/US2012/038165 patent/WO2012158811A2/en active Application Filing
- 2012-05-16 CA CA2836579A patent/CA2836579A1/en not_active Abandoned
- 2012-05-16 CN CN201280036015.2A patent/CN103687866A/zh active Pending
- 2012-05-16 EP EP12786631.7A patent/EP2710023A4/en not_active Withdrawn
- 2012-05-16 MX MX2013013570A patent/MX2013013570A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2710023A4 (en) | 2014-12-03 |
| EP2710023A2 (en) | 2014-03-26 |
| CA2836579A1 (en) | 2012-11-22 |
| CN103687866A (zh) | 2014-03-26 |
| WO2012158811A3 (en) | 2013-02-28 |
| US20140212382A1 (en) | 2014-07-31 |
| MX2013013570A (es) | 2014-07-09 |
| KR20140033446A (ko) | 2014-03-18 |
| WO2012158811A2 (en) | 2012-11-22 |
| RU2013125713A (ru) | 2015-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013029761A2 (pt) | pró-drogas de monofosfato de purina para tratamento de infecções virais | |
| HRP20181497T1 (hr) | Derivati purina za liječenje virusnih infekcija | |
| HK1214270A1 (zh) | 用於治療病毒感染和癌症的嘧啶核苷及其單磷酸酯前藥 | |
| HK1256490A1 (zh) | 用於治療病毒感染的嘧啶衍生物 | |
| CO6940431A2 (es) | Métodos para preparar análogos nucleotídicos antivirales | |
| DK2576534T3 (da) | 1-Substitueret-carba-nukleosid prodrugs til antiviral behandling | |
| CO6910196A2 (es) | Derivados de pirrolopirimidina y purina | |
| BR112013008017A2 (pt) | análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviral | |
| UA23989S (uk) | Комплект фар для автобуса | |
| BR112014007781A2 (pt) | compostos anti-virais | |
| EP2919792A4 (en) | 2 -ALKYNYL-SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF VIRUS DISEASES | |
| BR112013012998A2 (pt) | compostos para tratar infecções por vírus sincicial respiratório | |
| BRPI0807222A2 (pt) | Análogos de neucleosídeo para tratamento de infecções virais | |
| BR112013030370A2 (pt) | compostos de quinona para tratamento de doenças mediadas por ape1 | |
| EP2776438A4 (en) | SUBSTITUTED PURIN NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS | |
| BR112014007599A2 (pt) | compostos anti-virais | |
| CO6801768A2 (es) | Procesos para la preparación de inhibidores del virus de la hepatitis | |
| BR112013025021A2 (pt) | alisporivir para tratar infecções por vírus de hepatite c. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |